Novanta publishes 2025 annual report
PUBT·04/27/2026 21:18:10
Listen to the news
- Novanta annual report for year ended Dec. 31, 2025 outlined strategy centered on medical and advanced manufacturing platforms tied to robotics, automation, minimally invasive surgery.
- Bookings increased 14% for full year, supported by faster new product ramp and higher design-win activity.
- Portfolio mix continued to tilt toward medical, with medical end markets at 53% of sales; medical consumables reached 15% of revenue.
- Keonn acquisition closed April 8, 2025, adding RFID solutions with AI-enabled software to Medical Solutions segment.
- Priorities for 2026 set around organic growth execution, deployment of capital for acquisitions, completion of regionalized manufacturing strategy.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novanta Inc. published the original content used to generate this news brief on April 27, 2026, and is solely responsible for the information contained therein.
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.